In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative | Zendy

Francesco Barchiesi | Zendy; Maria Eleonora Milici | Zendy; Daniela Arzeni | Zendy; Anna Maria Schimizzi | Zendy; Giuseppe Pizzo | Zendy; Anna Giammanco | Zendy; D. Giannini | Zendy; Maurizio Manfrini | Zendy; Giorgio Scalise | Zendy; Chiara Beatrice Vicentini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative

Author(s) -

Francesco Barchiesi,

Maria Eleonora Milici,

Daniela Arzeni,

Anna Maria Schimizzi,

Giuseppe Pizzo,

Anna Giammanco,

D. Giannini,

Maurizio Manfrini,

Giorgio Scalise,

Chiara Beatrice Vicentini

Publication year - 2002

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkg019

Subject(s) - isothiazole , cryptococcosis , in vivo , cryptococcus neoformans , in vitro , derivative (finance) , microbiology and biotechnology , biology , cryptococcus , pharmacology , chemistry , biochemistry , medicinal chemistry , financial economics , economics

We investigated the activity of a pyrazolo-isothiazole derivative (G8) against Cryptococcus neoformans. A first screening test showed that G8 at 10 mg/L inhibited the growth of 14 of 15 clinical isolates tested. Killing experiments showed that fungicidal activity was achieved after 8 h of treatment with G8 at concentrations > or =10 mg/L. In a murine model of systemic cryptococcosis, G8 was effective at prolonging survival compared with the controls. Our data indicate that this new derivative has a potential therapeutic role in infections caused by C. neoformans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research